• Something wrong with this record ?

Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer

V. Liska, L. Holubec, V. Treska, J. Vrzalova, T. Skalicky, A. Sutnar, S. Kormunda, J. Bruha, O. Vycital, J. Finek, M. Pesta, L. Pecen, O. Topolcan

. 2011 ; 31 (4) : 1447-1451.

Language English Country Greece

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12027603

Grant support
NS9731 MZ0 CEP Register

AIM: The liver is the site of breast cancer metastasis in 50% of patients with advanced disease. Tumour markers have been demonstrated as being useful in follow-up of patients with breast cancer, in early detection of recurrence of breast cancer after radical surgical treatments, and in assessing oncologic therapy effect, but no study has been carried out on their usefullness in distinguishing benign liver lesions from breast cancer metastases. The aim of this study was therefore to evaluate the importance of tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen CA19-9 (CA19-9), thymidine kinase (TK), tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS) and cytokeratin 19 fragment (CYFRA 21-1) in differential diagnosis between benign liver lesions and liver metastases of breast cancer. PATIENTS AND METHODS: The study includes 3 groups: 22 patients with liver metastases of breast cancer; 39 patients with benign liver lesions (hemangioma, focal nodular hyperplasia, liver cyst, hepatocellular adenoma); and 21 patients without any liver disease or lesion that were operated on for benign extrahepatic diseases (groin hernia, varices of lower limbs) as a control group. The serum levels of tumour markers were assessed by means of immunoanalytical methods. RESULTS: Preoperative serum levels of CYFRA 21-1, TPA, TPS and CEA were significantly higher in patients with liver metastases of breast cancer in contrast to healthy controls and patients with benign liver lesions (p-value<0.05). Serum levels of CA19-9 and TK were higher in patients with malignancy in comparison with benign liver disease and healthy controls but these differences were not statistically significant. CONCLUSION: Tumour markers CEA, CYFRA 21-1, TPA and TPS can be recommended as a good tool for differential diagnosis between liver metastases of breast cancer and benign liver lesions.

000      
00000naa a2200000 a 4500
001      
bmc12027603
003      
CZ-PrNML
005      
20171213083600.0
007      
ta
008      
120817s2011 gr f 000 0#eng||
009      
AR
035    __
$a (PubMed)21508401
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Liska, Vaclav $u Department of Surgery, Charles University Prague, Pilsen, Czech Republic
245    10
$a Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer / $c V. Liska, L. Holubec, V. Treska, J. Vrzalova, T. Skalicky, A. Sutnar, S. Kormunda, J. Bruha, O. Vycital, J. Finek, M. Pesta, L. Pecen, O. Topolcan
520    9_
$a AIM: The liver is the site of breast cancer metastasis in 50% of patients with advanced disease. Tumour markers have been demonstrated as being useful in follow-up of patients with breast cancer, in early detection of recurrence of breast cancer after radical surgical treatments, and in assessing oncologic therapy effect, but no study has been carried out on their usefullness in distinguishing benign liver lesions from breast cancer metastases. The aim of this study was therefore to evaluate the importance of tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen CA19-9 (CA19-9), thymidine kinase (TK), tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS) and cytokeratin 19 fragment (CYFRA 21-1) in differential diagnosis between benign liver lesions and liver metastases of breast cancer. PATIENTS AND METHODS: The study includes 3 groups: 22 patients with liver metastases of breast cancer; 39 patients with benign liver lesions (hemangioma, focal nodular hyperplasia, liver cyst, hepatocellular adenoma); and 21 patients without any liver disease or lesion that were operated on for benign extrahepatic diseases (groin hernia, varices of lower limbs) as a control group. The serum levels of tumour markers were assessed by means of immunoanalytical methods. RESULTS: Preoperative serum levels of CYFRA 21-1, TPA, TPS and CEA were significantly higher in patients with liver metastases of breast cancer in contrast to healthy controls and patients with benign liver lesions (p-value<0.05). Serum levels of CA19-9 and TK were higher in patients with malignancy in comparison with benign liver disease and healthy controls but these differences were not statistically significant. CONCLUSION: Tumour markers CEA, CYFRA 21-1, TPA and TPS can be recommended as a good tool for differential diagnosis between liver metastases of breast cancer and benign liver lesions.
650    _2
$a antigeny nádorové $x krev $7 D000951
650    _2
$a prsy $x metabolismus $7 D001940
650    _2
$a nádory prsu $x krev $x diagnóza $7 D001943
650    _2
$a antigen CA-19-9 $x krev $7 D018395
650    _2
$a karcinoembryonální antigen $x krev $7 D002272
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kohortové studie $7 D015331
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a časná diagnóza $7 D042241
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a keratin-19 $x krev $7 D053539
650    _2
$a nádory jater $x krev $x diagnóza $x sekundární $7 D008113
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a thymidinkináza $x krev $7 D013937
650    _2
$a tkáňový polypeptidový antigen $x krev $7 D019396
650    _2
$a nádorové biomarkery $x krev $7 D014408
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Holubec, Luboš, $d 1972- $7 xx0068645 $u Department of Oncology, Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic; Department of Central Isotopic Laboratory, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Treska, Vladislav $u Department of Surgery, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Vrzalova, Jindra $u Department of Central Isotopic Laboratory, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Skalicky, Tomas $u Department of Surgery, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Sutnar, Alan $u Department of Surgery, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Kormunda, Stanislav $u Department of Central Isotopic Laboratory, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Bruha, Jan $u Department of Surgery, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Vycital, Ondrej $u Department of Surgery, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Finek, Jindrich $u Department of Oncology, Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Pesta, Martin $u Department of Central Isotopic Laboratory, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Pecen, Ladislav $u Department of Central Isotopic Laboratory, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
700    1_
$a Topolcan, Ondrej $u Department of Central Isotopic Laboratory, Medical School and Teaching Hospital Pilsen, Charles University Prague, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 31, č. 4 (2011), s. 1447-1451
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21508401 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20171213083748 $b ABA008
999    __
$a ok $b bmc $g 949645 $s 784949
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 31 $c 4 $d 1447-1451 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NS9731 $p MZ0
LZP    __
$a Pubmed-20120817/11/03

Find record

Citation metrics

Archiving options